QUEST informs readers of the latest advances in urologic prostate cancer research, especially detection, prevention, and treatment.

Looking for Risk Factors for Metastasis in Men with CRPC

Investigators looked for predictors of time to metastasis in men who had non-metastatic prostate cancer at diagnosis, were treated with androgen deprivation therapy (ADT), and then developed castration-resistant prostate cancer (CRPC). The analysis included 458 men with non-metastatic CRPC. A…

Read More

Optimal Timing for Androgen-Deprivation Therapy

ADT, also known as hormone therapy, is typically offered to patients who either have rising PSAs after being treated for prostate cancer or to patients who are not eligible for treatment to due age, life expectancy, or locally advanced disease….

Read More

Subscribe to Quest